Royce & Associates LP Increases Stock Position in NeoGenomics, Inc. (NASDAQ:NEO)

Royce & Associates LP increased its holdings in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 5.7% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 675,866 shares of the medical research company's stock after buying an additional 36,390 shares during the quarter. Royce & Associates LP owned about 0.53% of NeoGenomics worth $11,138,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of NEO. PNC Financial Services Group Inc. boosted its stake in shares of NeoGenomics by 5.2% in the 4th quarter. PNC Financial Services Group Inc. now owns 15,610 shares of the medical research company's stock worth $257,000 after buying an additional 770 shares during the last quarter. FMR LLC lifted its holdings in NeoGenomics by 7.6% in the third quarter. FMR LLC now owns 13,255 shares of the medical research company's stock valued at $196,000 after acquiring an additional 931 shares during the period. Blue Trust Inc. lifted its holdings in NeoGenomics by 33.2% in the fourth quarter. Blue Trust Inc. now owns 4,421 shares of the medical research company's stock valued at $73,000 after acquiring an additional 1,103 shares during the period. KBC Group NV grew its stake in shares of NeoGenomics by 33.1% during the 3rd quarter. KBC Group NV now owns 4,530 shares of the medical research company's stock valued at $67,000 after purchasing an additional 1,127 shares during the period. Finally, Versant Capital Management Inc grew its stake in shares of NeoGenomics by 174.9% during the 4th quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company's stock valued at $30,000 after purchasing an additional 1,142 shares during the period. 98.50% of the stock is currently owned by institutional investors.

Remove Ads

Wall Street Analyst Weigh In

NEO has been the topic of several recent research reports. Bank of America lowered their price objective on shares of NeoGenomics from $19.00 to $16.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 19th. Piper Sandler reduced their target price on shares of NeoGenomics from $21.00 to $18.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. The Goldman Sachs Group cut their price objective on shares of NeoGenomics from $20.00 to $18.00 and set a "buy" rating for the company in a research report on Tuesday, January 28th. Jefferies Financial Group started coverage on shares of NeoGenomics in a research report on Tuesday, December 10th. They set a "buy" rating and a $22.00 price objective for the company. Finally, Needham & Company LLC lowered their target price on NeoGenomics from $19.00 to $18.00 and set a "buy" rating on the stock in a research report on Wednesday, February 19th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $19.60.

NeoGenomics Price Performance

NASDAQ:NEO traded down $0.07 on Friday, reaching $9.86. 2,530,820 shares of the company's stock traded hands, compared to its average volume of 809,663. The stock has a 50-day simple moving average of $12.43 and a 200-day simple moving average of $14.62. NeoGenomics, Inc. has a 12 month low of $8.98 and a 12 month high of $19.12. The firm has a market cap of $1.27 billion, a PE ratio of -15.90 and a beta of 1.28. The company has a quick ratio of 1.91, a current ratio of 1.98 and a debt-to-equity ratio of 0.38.

NeoGenomics (NASDAQ:NEO - Get Free Report) last released its earnings results on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.05). NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. The business had revenue of $172.00 million for the quarter, compared to analysts' expectations of $173.40 million. Equities research analysts forecast that NeoGenomics, Inc. will post -0.2 earnings per share for the current year.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.